Status:

COMPLETED

Portable Transcranial Electrical Stimulation and Internet-Based Behavioral Therapy for Major Depression Study

Lead Sponsor:

University of Sao Paulo

Collaborating Sponsors:

Fundação de Amparo à Pesquisa do Estado de São Paulo

Conditions:

Major Depressive Disorder

Unipolar Depression

Eligibility:

All Genders

18-59 years

Phase:

NA

Brief Summary

First-line treatments for major depressive disorder (MDD), antidepressants and psychotherapy, are associated with refractoriness and discontinuation due to side effects, and logistical burdens, respec...

Detailed Description

Major depressive disorder (MDD) is a prevalent, debilitating and chronic mental disorder, characterized by frequent recurrences and resistance to first-line treatments: antidepressants and onsite cogn...

Eligibility Criteria

Inclusion

  • Diagnosis of major depressive disorder (MDD) per DSM-5 criteria
  • Hamilton Rating Scale (17-item version)-HDRS score ≥ 17 at baseline
  • Years of education ≥ 8
  • Having access to a smartphone with internet access at home
  • Treatment refractoriness ≤ 3 antidepressants, at optimal doses and for appropriate duration
  • No contraindications for tDCS (i.e., metallic plates on the head, brain devices, cochlear implants, cardiac pacemakers)
  • No suicidal ideation with planning, or attempted suicide, in the 4 weeks prior to baseline

Exclusion

  • Other psychiatric diagnoses (i.e., schizophrenia, schizoaffective disorder, bipolar disorder, obsessive compulsive disorder, attention-deficit and hyperactivity disorder, personality disorders, substance dependence and/or abuse disorders). Obs.: Anxiety disorders, as a comorbidity, will not be an exclusion criterium.
  • Suspected or confirmed pregnancy
  • Lactation
  • Severe clinical or neurological conditions, including Post-Acute Sequelae of COVID-19
  • Depressive symptoms better explained by other clinical conditions (i.e., hypothyroidism, anemia) or other psychiatric disorders.
  • Use of benzodiazepines \> 10mg diazepam or diazepam-equivalent per day

Key Trial Info

Start Date :

May 22 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 21 2022

Estimated Enrollment :

210 Patients enrolled

Trial Details

Trial ID

NCT04889976

Start Date

May 22 2021

End Date

October 21 2022

Last Update

November 1 2022

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Institute of Psychiatry, HC-FMUSP

São Paulo, São Paulo, Brazil

2

Hospital Universitário - USP

São Paulo, Brazil, 05508000